Opus Genetics, Inc.
IRDNASDAQHealthcare● Active
$4.03
+$0.00(+0.00%)
Market Cap$328024022
P/E Ratio—
52W High$5.81
52W Low$0.9
Opus Genetics, Inc. (IRD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IRD · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 21, 2026EPS Actual
-$0.19
Est. -$0.16 · -18.8%
Revenue
$0.00B
Est. $0.00B · +22.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 21, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
IRD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.15 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 21, 2026 | -$0.16 | -$0.19 | -18.8% | $0.00B | $0.00B | +22.9% |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.16 | -$0.75 | -368.8% | $0.00B | $0.00B | -26.3% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.14 | -$0.12 | +14.3% | $0.00B | $0.00B | +0.3% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.25 | -$0.12 | +52.0% | $0.00B | $0.00B | -6.5% |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.34 | -$0.32 | +5.9% | $0.00B | $0.00B | +28.5% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.34 | -$1.27 | -273.5% | $0.00B | $0.00B | +27.0% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.30 | -$0.29 | +3.3% | $0.00B | $0.01B | -65.2% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 21, 2026Miss
EPS Actual
-$0.19
EPS Est.
-$0.16
EPS Surpr.
-18.8%
Revenue
$0.00B
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.75
EPS Est.
-$0.16
EPS Surpr.
-368.8%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.14
EPS Surpr.
+14.3%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.25
EPS Surpr.
+52.0%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.34
EPS Surpr.
+5.9%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$1.27
EPS Est.
-$0.34
EPS Surpr.
-273.5%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.29
EPS Est.
-$0.30
EPS Surpr.
+3.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.01 | $0.32 | $0.67 | 5 |
| Q3 FY2028 | $-0.01 | $0.29 | $0.60 | 5 |
| Q2 FY2028 | $-0.01 | $0.25 | $0.51 | 6 |
| Q1 FY2028 | $-0.01 | $0.22 | $0.45 | 3 |
| Q4 FY2027 | $-0.28 | $-0.14 | $0.00 | 2 |
| Q3 FY2027 | $-0.35 | $-0.17 | $0.01 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 9 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 21, 2026 | -18.8% | $4.44 | $4.29 | -3.38% |
| ▼ Q2 FY2026 | May 12, 2026 | -368.8% | $5.12 | $5.18 | +1.17% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +14.3% | $1.97 | $1.92 | -2.54% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +52.0% | $1.11 | $1.10 | -0.90% |
| ▲ Q2 FY2025 | May 15, 2025 | +5.9% | $0.95 | $0.95 | +0.00% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -273.5% | $1.01 | $0.98 | -2.79% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +3.3% | $1.17 | $1.14 | -2.56% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -20.0% | No price data | $1.29 | — |
Q2 FY2026-3.38%
Report Date
May 21, 2026
EPS Beat/Miss
-18.8%
Price Before
$4.44
Price After
$4.29
Q2 FY2026+1.17%
Report Date
May 12, 2026
EPS Beat/Miss
-368.8%
Price Before
$5.12
Price After
$5.18
Q4 FY2025-2.54%
Report Date
Nov 12, 2025
EPS Beat/Miss
+14.3%
Price Before
$1.97
Price After
$1.92
Q3 FY2025-0.90%
Report Date
Aug 13, 2025
EPS Beat/Miss
+52.0%
Price Before
$1.11
Price After
$1.10
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
+5.9%
Price Before
$0.95
Price After
$0.95
Q1 FY2025-2.79%
Report Date
Mar 31, 2025
EPS Beat/Miss
-273.5%
Price Before
$1.01
Price After
$0.98
Q4 FY2024-2.56%
Report Date
Nov 12, 2024
EPS Beat/Miss
+3.3%
Price Before
$1.17
Price After
$1.14
Q3 FY2024—
Report Date
Aug 13, 2024
EPS Beat/Miss
-20.0%
Price Before
—
Price After
$1.29
Avg Beat Reaction-1.50%
Avg Miss Reaction-1.67%
Beat Rate4 / 8 quarters
Largest Move-3.38% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IRD ends December
Opus Genetics, Inc. (IRD) most recently reported earnings on May 21, 2026 for Q2 FY2026, posting EPS of $-0.19 — missing the analyst consensus of $-0.16 by -18.8%. The next IRD earnings date is expected around September 1, 2026.
Each quarter, investors track IRD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IRD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IRD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IRD earnings · 5 questionsOpus Genetics, Inc.'s next earnings report is expected around September 1, 2026. IRD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IRD historically reports after market close (AMC).
IRD earnings datewhen is IRD earningsIRD next earnings datewhen does IRD report earningsIRD earnings calendar
▸ Source: FMP · Opus Genetics, Inc. SEC filings · US GAAP · Opus Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026